All In MedTech

Device Trial Radar · NCT05001893

Clinical Safety and Efficacy of S53P4 Bioactive Glass Putty in Spinal Fusion Surgery

Clinical Safety and Efficacy of S53P4 Bioactive Glass Putty in Spinal Fusion Surgery: Post Market Clinical Follow-up Study

Last checked: Nov 20, 2026Latest source record: Aug 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

500

Planned (sponsor's estimate)

Start

May 3, 2021

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Bonalive Biomaterials LtdNot on our public-company list
Sponsor type
Industry
Collaborators
Turku University Hospital
First posted
Aug 12, 2021

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No

Summary

As written by the sponsor on the registry.

A retrospective, single-tertiary centre observational study. The study population consists mainly of patients with instrumented posterolateral spine fusion operated at the Department of Neurosurgery or at the Department of Orthopaedics and Traumatology in the Turku University Hospital. Also, patients with non-instrumented posterolateral spine fusion, interbody spine fusion, and a combination of posterolateral and interbody spine fusion are included. The approximate number of the above-mentioned operations with BonAlive® putty is 400 - 500 between September 2013 and April 2021. In the operations, the BonAlive® putty was used either alone, together with autologous bone (AB) chips, with milled allogenous bone chips, with demineralized bone matrix (DBM), with other synthetic bone grafts, or with a combination of the above-mentioned.

Conditions

  • Spine Fusion
  • Spinal Deformity

Interventions

  • S53P4 bioactive glass puttyDevice

    Bonalive putty/putty MIS paste is a synthetic, bioactive, osteoconductive, osteostimulative bone void filler for filling, reconstruction, and regeneration of bone defects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the clinical efficacy of BonAlive® (S53P4 bioactive glass) putty in spine fusion operations when used alone and together with autologous bone.Time frame: 24 months
  2. Clinical outcomes are for pain VAS:Time frame: 24 months
  3. EQ-5D cost effectiviness questionnaires.Time frame: 24 months

2 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Turku University Hospital Department of Neurosurgery

    Turku, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.